The Blue Nature by Suzanne Hamilton Free

Whether these 2 malignancies are biologically similar remains to be determined and is an area of research activity in our lab. In contrast, in developing nations, Burkitt Lymphoma is of a sporadic form, in some cases also associated with EBV infection. Burkitt lymphoma was first described in children in Uganda by Denis Burkitt in what has become known as endemic Burkitt Lymphoma, a disease associated with EBV infection in malaria endemic regions. Applying CRISPR screens, we determine bypass signalling tracks that might be therapeutically targetable to re sensitise cells to ALK inhibitors or used as alternative treatment approaches.Īnother aspect of our research focuses on Burkitt Lymphoma, a cancer of the B cells of our immune systems. Our research also extends to understanding mechanisms of therapy resistance with a focus on ALK inhibitors used to treat ALCL, neuroblastoma and lung cancer.

These research themes run alongside our ongoing efforts to elucidate the signal transduction pathways initiated by NPM-ALK and our efforts to generate ALK-specific inhibitor compounds. We are addressing several theories employing the mouse models oncogene addiction, lymphoma initiating cells and the contribution of antigenic stimulation to lymphomagenesis. We are now refining these models so that they more closely minic the human disease at both phenotypic and genetic levels.

We have generated mouse models demonstrating the causal role of NPM-ALK in the development of ALCL. The consistent presence of this genomic abnormality with this specific disease phenotype suggests it plays a role in lymphomagenesis. ALCL is asociated with expression of the Nucelophosmin-Anaplastic Lymphoma Kinase oncogene (NPM-ALK) generated as a result of the t(2 5). Our research focusses on dissecting mechanisms of lymphomagenesis using anaplastic large cell lymphoma (ALCL) as our working model.

The Blue Nature by Suzanne Hamilton Free